Wakamoto Pharmaceutical Co., Ltd. (JP:4512)

:4512

4512

Wakamoto Pharmaceutical Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4512 full AI Analyst Report?

Wakamoto Pharmaceutical Co., Ltd. (4512) Price & Analysis

0 Followers

4512 Stock Chart & Stats

¥286.00

-¥4.00(-1.79%)

At close: Jan 08 4:00 PM EST

¥286.00

-¥4.00(-1.79%)

Day’s Range― - ―

52-Week Range¥271.00 - ¥380.00

Previous CloseN/A

Volume100.70K

Average Volume (3M)65.94K

Market Cap

¥12.25B

Enterprise Value¥10.68B

Total Cash (Recent Filing)¥3.56B

Total Debt (Recent Filing)¥100.00M

Price to Earnings (P/E)7.1

Beta0.41

Next Earnings

May 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)-5.12

Shares Outstanding34,838,326

10 Day Avg. Volume55,010

30 Day Avg. Volume65,936

Financial Highlights & Ratios

PEG Ratio-4.19

Price to Book (P/B)0.95

Price to Sales (P/S)1.41

P/FCF Ratio-10.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet / Low LeverageA robust equity position and low debt-to-equity ratio provide durable financial flexibility. Over the next 2-6 months this supports continued R&D and product investment, cushions operating volatility, and reduces refinancing risk versus peers with higher leverage.

Recent Top-line GrowthReported revenue growth of ~16.8% indicates positive demand momentum for core products. Given the company's recurring healthcare product model, sustained top-line growth can translate into steadier cash flows and better scale economics over quarters if product mix and distribution remain stable.

Stable Gross Margins; Improving EBITDAStable gross margins combined with an improving EBITDA margin point to retainable core profitability and better operating control. If sustained, these trends can permit reinvestment or margin expansion as fixed costs are absorbed and operational efficiencies persist.

Bears Say

Declining Net Income; Negative EBITDeclining net income and a persistently negative EBIT margin indicate structural operating inefficiency. Over several quarters this erodes operating leverage, limits internal funding for growth, and undermines the company's ability to convert revenue into sustainable shareholder returns.

Negative Operating And Free Cash FlowNegative operating and free cash flow show difficulty turning accounting profits into cash. Persisting cash conversion issues constrain capex, R&D, and working capital, increasing reliance on external financing or asset sales and raising medium-term liquidity and execution risk.

Diminishing Return On EquityA healthy equity base with falling ROE signals that capital is not being deployed profitably. If returns remain depressed, it points to allocation inefficiency and may pressure management to restructure operations or seek lower-risk uses of capital, reducing long-term value creation.

4512 FAQ

What was Wakamoto Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Wakamoto Pharmaceutical Co., Ltd. lowest stock price was ¥271.00 and its highest was ¥380.00 in the past 12 months.

What is Wakamoto Pharmaceutical Co., Ltd.’s market cap?

Wakamoto Pharmaceutical Co., Ltd.’s market cap is ¥12.25B.

When is Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Wakamoto Pharmaceutical Co., Ltd.’s upcoming earnings report date is May 15, 2026 which is in 9 days.

How were Wakamoto Pharmaceutical Co., Ltd.’s earnings last quarter?

Wakamoto Pharmaceutical Co., Ltd. released its earnings results on Feb 04, 2026. The company reported ¥10.05 earnings per share for the quarter, beating the consensus estimate of N/A by ¥10.05.

Is Wakamoto Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Wakamoto Pharmaceutical Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wakamoto Pharmaceutical Co., Ltd. pay dividends?

Wakamoto Pharmaceutical Co., Ltd. pays a Annually dividend of ¥3 which represents an annual dividend yield of 1.06%. See more information on Wakamoto Pharmaceutical Co., Ltd. dividends here

What is Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate?

Wakamoto Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wakamoto Pharmaceutical Co., Ltd. have?

Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding.

What happened to Wakamoto Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Wakamoto Pharmaceutical Co., Ltd. reported an EPS of ¥10.05 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Wakamoto Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4512

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wakamoto Pharmaceutical Co., Ltd.

Wakamoto Pharmaceutical Co., Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong Wakamoto, a gastrointestinal drug for digestion, intestinal regulation, and nutritional supplementation. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943. Wakamoto Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.